Retatrutide

Retatrutide  is an investigational triple hormone receptor agonist being developed by Eli Lilly for the treatment of obesity and type 2 diabetes. It targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors—three key hormones involved in metabolism, appetite, and glucose regulation.

Benefits of Retatutide:

• Significant weight loss: In clinical trials, participants experienced substantial reductions in body weight, often more than what is seen with existing GLP-1-only drugs like semaglutide.
• Improved blood sugar control: Helps lower HbA1c levels in people with type 2 diabetes.
• Enhanced metabolic health: May improve insulin sensitivity, lipid profiles, and liver fat reduction.
• Appetite suppression: Reduces hunger and food intake by acting on appetite-regulating centers in the brain.

It’s considered part of a new generation of multi-agonist therapies that aim to provide greater efficacy than current weight loss and diabetes treatments. It’s still under clinical investigation, but early results are very promising.

Disclaimer: The following information is provided strictly for research purposes only. It is not intended for human or veterinary use outside of approved, controlled studies. Always follow applicable laws, institutional guidelines, and ethical standards.